Pharma & Biotech News , from our Global Correspondents
Refine search
Biotechnology
Russian drugmaker Pharmasyntez and China's Hualan Bio will join forces on the development of new drugs and technology transfer, according to the partners, The Pharma Letter’s local correspondent reports. 22 October 2025
Pharmaceutical
Although clinical research is essential to discover new treatment alternatives, improve diagnostic processes and prevention tools, allowing us to gai years of life expectancy and reduce the number of deaths, and also imnpacts the economic and social development of countries, Latin America's participation in these studies is still limited compared to other regions such as Europe or the USA. 8 October 2025
Generics
In a strategic move to rebalance trade with India, Russian President Vladimir Putin has directed his government to ramp up imports of Indian pharmaceuticals and agricultural products. 6 October 2025
Generics
In a move reminiscent of past trade disputes, China appears to have launched a price war on key active pharmaceutical ingredients (APIs), directly challenging India's push for self-reliance in the pharmaceutical sector. 18 September 2025
Biotechnology
Chinese biotechs face unfamiliar challenges as they explore advanced biological therapies, a topic of discussion at the Frost & Sullivan’s 9 September 2025
Pharmaceutical
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder that affects approximately 1 in 10,000 live births.1 9 September 2025
Pharmaceutical
Dr Vinay Prasad’s short but eventful tenure has drawn significant attention from the pharmaceutical industry. 8 September 2025
Pharmaceutical
Russia is experiencing a boom of sales of anxiolytics - tranquilizers that reduce anxiety and fear, which have been growing for the third year in a row. 5 September 2025
Pharmaceutical
Global pharma companies supplying their drugs for the list of vital medicines in Russia may face with serious difficulties in the local market in the short term due to the ever tightening-requirements from the Russian state, The Pharma Letter’s local correspondent reports. 4 September 2025
Biotechnology
In a significant move toward self-reliance, the Indian government is doubling down on its commitment to a homegrown biotechnology sector, reports The Pharma Letter’s India correspondent. 3 September 2025
Biotechnology
China is leveraging its vast resources to become a top global supplier of cost effective "best-in-class" treatments, a shift that could reshape the global pharmaceutical landscape. This was a key takeaway from Frost & Sullivan's annual Life Sciences New Investment Summit last week. 2 September 2025
Pharmaceutical
Hypertension remains one of Latin America’s leading killers despite new treatments, with more than two million deaths every year and nearly half occurring before age 70, according to a new Pan American Health Organization (PAHO) study. 1 September 2025
Pharmaceutical
The range of drugs available in the Russian market may significantly decrease in the short term due to protectionist measures imposed by the government in regard of domestic drugs, which are purchased at state tenders. 29 August 2025
Biotechnology
Russian drugmaker R-Pharm is searching buyers for its flagship factory in Germany in the city of Illertissen, which was acquired by the company from the American firm Pfizer back in 2014, The Pharma Letter’s local correspondent reports. 26 August 2025
Biotechnology
Castleman’s disease (CD) refers to a group of rare lymphoproliferative disorders characterized by abnormal lymph node architecture and systemic inflammation. 12 August 2025
Pharmaceutical
The US Food and Drug Administration’s (FDA) recent moves around GLP-1-based combination therapies are telling, not just about the agency’s evolving stance on obesity treatment, but about how it is reshaping its regulatory playbook for metabolic disease. 11 August 2025
Generics
India’s pharmaceutical sector continues to assert its dominance on the global stage, driven by a surge in generic drug launches that are reshaping access to affordable healthcare. A flurry of filings and approvals are turning India’s pharma sector into a hotbed of innovation and investment, reports The Pharma Letter’s India correspondent. 8 August 2025
Pharmaceutical
The Russian government plans to increase procurements of drugs against hepatitis C due to a significant increase in the number of cases of such disease in the country in recent years, The Pharma Letter’s local correspondent reports. 6 August 2025
Generics
Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local correspondent. 5 August 2025
Biosimilars
US tariffs have served as a significant catalyst for Indian pharmaceutical companies to reassess their strategies, leading to accelerated efforts in market and product diversification. The challenging environment has encouraged a strategic shift towards higher margin products, reports The Pharma Letter’s India correspondent. 31 July 2025
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Pharmaceutical
Russian drugmaker Pharmstandard plans to build a new complex for the production of live vaccines in the Technopolis special economic zone in the Moscow region, which is expected to be one of the largest of such kind in the country, reports The Pharma Letter’s local correspondent. 15 June 2026
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Generics
Russian pharmaceutical company KhimRar Group is expanding its capacities for the production of active pharmaceutical ingredients (APIs) by 10 times up to 50 tons per year, reports The Pharma Letter’s local correspondent. 8 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Biotechnology
India’s biotechnology sector is entering a transformative phase, with domestic and global players betting on the country’s scientific talent and cost advantages to make advanced therapies such as CAR-T cell therapy more accessible, reports The Pharma Letter’s India correspondent. 1 June 2026
Generics
Indian pharmaceutical companies have pledged an unprecedented $19.1 billion in investments across the USA, marking a watershed moment in bilateral healthcare collaboration. 11 May 2026
Generics
The share of generics in the Russian pharmaceutical market will grow in the coming years, both in the pharmacy segment and in government procurement, according to latest forecasts made by experts of the Russian analyst agency in the field of pharmaceutics DSM Group. 11 May 2026
Generics
Russia is experiencing a boom of sales of obesity drugs, which is mainly due to the recent launch of some domestically developed drugs in this market segment, reports The Pharma Letter’s local correspondent. 8 May 2026
Biotechnology
Russia has faced an acute shortage of Abraxane (paclitaxel), a drug, which is produced by US pharma major Bristol-Myers Squibb and which is designed for the treatment of patients with breast and pancreatic cancer, The Pharma Letter’s local correspondent reports. 5 May 2026
Biotechnology
April 2026 marked a period of cautious progress in rare disease therapeutics. A series of regulatory approvals, research developments, and policy initiatives signalled continued momentum, particularly in pediatric nephrology and oncology. 2 May 2026
Pharmaceutical
Over 500 new drugs are expected to be introduced to the Russian market this year, including through localization, according to recent statements of Russia’s Health Minister Mikhail Murashko. 1 May 2026
Biotechnology
While the geopolitical climate between Washington and Beijing grows increasingly chilled, the Boston-based investor behind the in vivo CAR-T biotech Capstan (acquired by AbbVie) and flu drug developer Cidara (now part of Merck & Co) is choosing to lean in rather than pull away. 1 May 2026
Pharmaceutical
Even as Sun Pharmaceutical Industries edges ahead with its ambitious $13 billion bid to acquire US-based Organon, in what could become the largest overseas acquisition ever attempted by an Indian drugmaker, the move underscores a broader push by Indian pharmaceutical companies to expand their global footprint through strategic acquisitions, reports The Pharma Letter’s India correspondent. 27 April 2026
Generics
Axelpharm, the Russian manufacturer of anticancer generics, may suspend operations due to fines from the local antitrust regulator the Federal Antimonopoly Service (FAS), which were imposed for the company’s participation in patent disputes. 21 April 2026
Pharmaceutical
Russia plans to increase public procurements of anti-cancer drugs that will be part of a new national project, which aims to ensure two-thirds of cancer patients survive five years or more after diagnosis with cancer by 2030, reports The Pharma Letter’s local correspondent. 20 April 2026
Pharmaceutical
The US Food and Drug Administration (FDA) is ramping up government efforts to curb misinformation on prescription drugs that endanger public health. This is in line with the presidential memorandum, which seeks to address misleading direct-to-consumer (DTC) prescription drug advertisements. 20 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Generics
India has moved ahead in developing indigenous capacity for cell and gene therapies, with regulatory bodies issuing national guidelines to ensure safe and ethical deployment of CRISPR-based technologies. 3 April 2026
Biotechnology
March 2026 marked a significant inflection point for rare disease therapeutics, as regulatory momentum, policy pressure, and scientific innovation converged. 30 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze